SYnAbs signs a research agreement with Domain Therapeutics to discover therapeutic antibodies on GPCRs
SYnAbs and Domain Therapeutics enter into a strategic partnership for the discovery and development of therapeutic antibodies targeting complex G Protein Coupled Receptor targets for immuno-oncology indications
G protein-coupled endothelin receptors and their natural and therapeutic ligands
From the discovery of an unique peptide ligand to the clinical relevance of ETA and ETB receptors and the current therapeutic pipeline of small molecules and monoclonal antibodies targeting these GPCR transmembrane proteins

Glutamate transporter : a brief history of excitatory amino acid transmembrane proteins
SYnAbs has developed R&D and therapeutic monoclonal antibodies against transporters and ion channel such as glutamate EAAT transmembrane targets thanks to peptide and syngeneic cell immunization strategies
TACA, promising oncology targets?
SYnAbs develops therapeutic IgG antibodies highly specific to carbohydrates by combining unique technologies and expertise to break immune tolerance in rat-LOU and transgenic animal species

Therapeutic trends of G protein-coupled receptor drugs as Antibody Drug Conjugates candidates
SYnAbs can help you develop therapeutic antibody-drug conjugates by specifically targeting transmembrane proteins using innovative proprietary technologies.
CX3CR1, GPCR CX3C chemokine receptor 1 (CX3CR1): transmembrane receptor of therapeutic interest?
SYnAbs discovers antibodies to transmembrane proteins including GPCR chemokine receptors thanks to unique cell immunization technology and expertise

Immuno-Oncology Therapeutic Potential of Adenosine Receptors: Targeting the Purinergic Pathway
SYnAbs develops therapeutic monoclonal antibodies with agonistic or antagonistic effects to highly homologous G Protein-Coupled Receptors transmembrane proteins
MARK & MARL SYnAbs mouse anti-rat light chain monoclonals
SYnAbs mouse anti-rat light chains to monitore immune isotypic response, quantify circulating rat therapeutic antibody candidates, and easily purify all rat isotypes without cross-binding to bovine serum immunoglobulins

LO-MG SYnAbs rat-anti IgG mouse monoclonals
Secondary monoclonal antibodies · 26. February 2022
SYnAbs rat anti-mouse IgG to monitore immune isotypic response to infections and vaccines, better comprehend B-cells & T-cells interactions and pathology-related mechanisms in transgenic mouse models
The therapeutic challenges of receptor tyrosine kinases
SYnAbs generates custom therapeutic monoclonal antibodies to receptor tyrosine kinases (RTKs) thanks to proprietary technologies and unique expertise

Show more